The lifetime risk of breast cancer associated with pathogenic variants in NF1 is approximately 20%, with a significant risk of developing breast cancer under the age of 50 [30,169], such that it has been suggested that patients with NF1 should be referred for enhanced breast cancer screening [170]. The gene discussed is NF1; the disease is breast carcinoma.